Almirall, S.A. (ALME.XC)

9.66 0.00 (0.00%) At close: 02:43PM BST

Almirall, S.A.

Ronda General Mitre, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full-time employees: 1,904

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Carlos Gallardo Piqué	CEO, President, Member of Management Board & Chairman of the Board	50k	N/A	1972
Mr. Michael McClellan	CFO & Member of Management Board	N/A	N/A	1972
Mr. Eloi Crespo Cervera	Chief Industrial Operations Officer & Member of Management Board	N/A	N/A	N/A
Mr. Esteve Conesa Panicot	Chief People & Culture Officer and Member of Management Board	N/A	N/A	N/A
Dr. Volker Koscielny	Chief Medical Officer & Member of Management Board	N/A	N/A	N/A
Dr. Karl Ziegelbauer	Chief Scientific Officer & Member of Management Board	N/A	N/A	N/A
Mr. Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	N/A	N/A	N/A
Ms. Isabel Cristina Gomes	Company Vice Secretary,Chief Legal Officer, General Counsel & Member of Management Board	N/A	N/A	N/A
Ms. Mercedes Diz Lopez	Chief Marketing Officer & Member of Management Board	N/A	N/A	N/A
Mr. Pablo Divasson del Fraile	Senior Director of Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2015, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Corporate governance

Almirall, S.A.’s ISS governance QualityScore as of 1 June 2024 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.